Syncona Shs GBP (GB:SYNC) has released an update.
Syncona Ltd, a prominent life science investor, has announced John Roche’s appointment as an independent Non-Executive Director, effective from October 1, 2024. Roche, a former PwC partner with substantial financial experience and expertise in audit and advisory services, will contribute to the company’s board and join the Audit Committee. Syncona, focused on investing in life science companies to improve patient treatment options and deliver shareholder returns, welcomes Roche’s breadth of knowledge as it pursues its long-term growth strategy.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
